Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mandatory Provider Training For Opioids Embraced By PhRMA

Executive Summary

Trade association members also commit tens of millions of dollars to set up addiction prevention programs and create new health care tools.

You may also be interested in...



Drug Safety: FDA Pushes To Publicly Release REMS Assessments, Says It Will Improve Plan Design

Proposal would allow stakeholders to see data on REMS goals like provider training and the US FDA’s conclusions about their effectiveness.

US FDA Needs ‘More Streamlined’ REMS Enforcement Authority, Inspector General Says

Additional power would allow the agency to punish 'simple' REMS violations and improve administration of risk management programs, according to a new report looking at FDA's oversight of opioids.

Opioid REMS Increases Nearly Six-Fold As US FDA Adds Immediate-Release Products

Basically every doctor prescribing any opioid is now covered by the REMS, but training remains voluntary. 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS122131

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel